Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Aegis Capital Corp. Announces Key Additions To Health Care Equity Research Department

Aegis Capital has been in business for 26 years and maintains a conflict-free service platform catering to the needs of private clients, institutions, and corporations. The full service investment banking firm has clients from all over the globe and 12 locations in the United States.

The company recently announced that it had made two very important hires for its newly-established Health Care Equity Research Department. Aegis brought on board Dr. Raghuram Selvaraju, Ph.D., who was formerly a senior vice-president and senior biotechnology analyst with Morgan Joseph TriArtisan. He will be responsible for actually setting up Aegis Capital's new Health Care Research Department.

Dr. Selvaraju started in the securities industries with Rodman & Renshaw as a biotechnology equity research analyst. He was ranked as the top biotech analyst in the Wall Street Journal's 'Best on the Street' survey in 2006. Dr. Selvaraju went on to become the head of healthcare equity research for Hapoalim Securities. While there, he was regularly featured on many media outlets, including Bloomberg TV, CNBC, Reuters/AP, The Wall Street Journal, Barron's, and BioWorld Today.

His industry experience began at Europe's largest biotechnology company, Serono S.A., where he started out as a technician designing models and user interfaces for analysis of gene expression data. He went to work as a pharmaceutical researcher, leading teams developing animal models to identify novel therapeutic products.

Dr. Selvaraju discovered the first novel protein candidate ever developed entirely at Serono. This led him to becoming the youngest-ever recipient of Serono's Inventorship Award for exceptional innovation and creativity.

Joining Dr. Selvaraju at Aegis Capital's new department will be Dr. Yi Chen, Ph.D., a former equity research associate at Morgan Joseph TriArtisan. He has been associated with Zhang Capital Management as an associate for trading support. Additionally, Dr. Chen was a post-doctoral researcher in molecular and cell biology with the Research Foundation of the City University of New York.

Additional information about Aegis Capital Corporation can be found at the following website

Please see disclaimer on the MissionIR website